vs
Side-by-side financial comparison of OXFORD INDUSTRIES INC (OXM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -20.7%, a 22.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -0.2%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.0%).
Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OXM vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $307.3M | $177.4M |
| Net Profit | $-63.7M | $2.9M |
| Gross Margin | 60.3% | — |
| Operating Margin | -27.7% | 3.9% |
| Net Margin | -20.7% | 1.6% |
| Revenue YoY | -0.2% | 5.0% |
| Net Profit YoY | -1517.6% | — |
| EPS (diluted) | $-4.28 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $307.3M | $196.9M | ||
| Q3 25 | $403.1M | $179.5M | ||
| Q2 25 | $392.9M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $308.0M | $187.3M | ||
| Q3 24 | $419.9M | $168.6M | ||
| Q2 24 | $398.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-63.7M | — | ||
| Q3 25 | $16.7M | $5.4M | ||
| Q2 25 | $26.2M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $40.6M | $-143.5M | ||
| Q2 24 | $38.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 60.3% | 79.5% | ||
| Q3 25 | 61.4% | 80.9% | ||
| Q2 25 | 64.2% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 63.1% | 78.7% | ||
| Q3 24 | 63.1% | 76.9% | ||
| Q2 24 | 64.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -27.7% | 1.2% | ||
| Q3 25 | 6.3% | 3.5% | ||
| Q2 25 | 9.2% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | -2.0% | 13.2% | ||
| Q3 24 | 12.5% | -82.8% | ||
| Q2 24 | 13.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -20.7% | — | ||
| Q3 25 | 4.1% | 3.0% | ||
| Q2 25 | 6.7% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | -1.3% | — | ||
| Q3 24 | 9.7% | -85.1% | ||
| Q2 24 | 9.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-4.28 | $0.05 | ||
| Q3 25 | $1.12 | $0.12 | ||
| Q2 25 | $1.70 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $-0.25 | $0.38 | ||
| Q3 24 | $2.57 | $-3.11 | ||
| Q2 24 | $2.42 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.0M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $528.0M | $653.9M |
| Total Assets | $1.3B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $8.0M | $238.4M | ||
| Q3 25 | $6.9M | $246.3M | ||
| Q2 25 | $8.2M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $7.0M | $484.6M | ||
| Q3 24 | $18.4M | $453.8M | ||
| Q2 24 | $7.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $528.0M | $693.1M | ||
| Q3 25 | $597.1M | $727.2M | ||
| Q2 25 | $592.4M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $612.2M | $778.3M | ||
| Q3 24 | $621.6M | $749.6M | ||
| Q2 24 | $592.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.1M | — |
| Free Cash FlowOCF − Capex | $-47.9M | — |
| FCF MarginFCF / Revenue | -15.6% | — |
| Capex IntensityCapex / Revenue | 12.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-79.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-9.1M | $43.7M | ||
| Q3 25 | $83.5M | $60.8M | ||
| Q2 25 | $-3.9M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $-18.2M | $33.1M | ||
| Q3 24 | $88.8M | $53.9M | ||
| Q2 24 | $32.9M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-47.9M | $43.5M | ||
| Q3 25 | $52.3M | $57.0M | ||
| Q2 25 | $-27.4M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $-56.9M | $31.0M | ||
| Q3 24 | $47.2M | $49.8M | ||
| Q2 24 | $21.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -15.6% | 22.1% | ||
| Q3 25 | 13.0% | 31.7% | ||
| Q2 25 | -7.0% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | -18.5% | 16.6% | ||
| Q3 24 | 11.2% | 29.6% | ||
| Q2 24 | 5.3% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | 0.1% | ||
| Q3 25 | 7.7% | 2.2% | ||
| Q2 25 | 6.0% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 12.6% | 1.1% | ||
| Q3 24 | 9.9% | 2.4% | ||
| Q2 24 | 3.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 5.00× | 11.20× | ||
| Q2 25 | -0.15× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.19× | — | ||
| Q2 24 | 0.86× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OXM
| Sales Channel Retail | $162.9M | 53% |
| Sales Channel Wholesale | $61.3M | 20% |
| Johnny Was | $45.4M | 15% |
| Sales Channel Food And Beverage | $29.3M | 10% |
| Other Foreign Countries | $9.0M | 3% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
